Clinic
Inspira Medical Centers, INC.
Inspira Medical Centers, INC. was paid $27.14M by Medicaid between Dec 2019 and Oct 2024, across 175 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoINSPIRA MEDICAL CENTERS, INC.
WOODBURY, NJ 08096
WOODBURY, NJ 08096
33aNPI1972141091assigned 12/19/2019
33bProvider typePhysical Therapy Clinic/Center
28Total paid$27.14M
24GClaims427,703
24DCodes billed175
24AFirst – last monthDec 2019 – Oct 2024
Compared with peers
Next to other Physical Therapy Clinic/Center providers in New Jersey
Rank by total paid#1 of 92
Median peer was paid$61K
This provider vs. median447×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 4,119 | $240K | |
| 2020 | 77,117 | $4.45M | |
| 2021 | 91,902 | $5.11M | |
| 2022 | 93,498 | $6.12M | |
| 2023 | 96,788 | $6.74M | |
| 2024incomplete | 64,279 | $4.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 15,623 | 14,424 | $5.43M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 20% | 16,319 | 1,619 | $5.38M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 16,289 | 14,961 | $4.60M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 6,778 | 6,375 | $3.49M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 8.4% | 27,096 | 10,746 | $2.29M |
| G0378 | Hospital observation service, per hour | 3.3% | 1,076 | 909 | $898K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 4,221 | 3,914 | $613K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 8,754 | 7,914 | $286K |
| 95806 | <1% | 184 | 179 | $222K | |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | <1% | 2,456 | 2,082 | $211K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 4,312 | 2,869 | $209K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,300 | 2,215 | $187K |
163 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 351 | $179K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,441 | $172K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,345 | $169K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,956 | $158K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,577 | $109K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,299 | $102K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,024 | $101K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,662 | $101K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,581 | $95K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,833 | $90K |
| 93975 | <1% | 1,249 | $81K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,729 | $79K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,950 | $75K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,948 | $74K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,267 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,513 | $68K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,248 | $60K |
| 87631 | <1% | 1,599 | $57K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,876 | $57K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,895 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,052 | $53K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,057 | $50K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,345 | $49K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 792 | $46K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,245 | $44K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 795 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,206 | $37K |
| 76801 | <1% | 902 | $37K | |
| OP279 | <1% | 1,093 | $36K | |
| 80053 | Comprehensive metabolic panel | <1% | 9,558 | $35K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,715 | $35K |
| 94760 | <1% | 16,721 | $35K | |
| 76830 | Ultrasound, transvaginal | <1% | 691 | $34K |
| 36000 | <1% | 2,812 | $31K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,417 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,446 | $28K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 346 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 982 | $26K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,546 | $25K |
| OP259 | <1% | 16,606 | $25K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,118 | $22K |
| 93041 | <1% | 2,359 | $22K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,475 | $21K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 469 | $20K |
| 84484 | <1% | 3,975 | $19K | |
| 73630 | <1% | 1,361 | $18K | |
| 87581 | <1% | 1,466 | $18K | |
| 87486 | <1% | 1,467 | $18K | |
| 96112 | <1% | 102 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 805 | $17K |
| 73130 | <1% | 1,147 | $16K | |
| 73564 | <1% | 1,054 | $16K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $15K |
| 96113 | <1% | 101 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,479 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 465 | $14K |
| 80320 | <1% | 2,948 | $13K | |
| 73610 | <1% | 1,009 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 556 | $12K |
| 86901 | <1% | 604 | $12K | |
| 96376 | <1% | 1,140 | $12K | |
| 93971 | <1% | 202 | $11K | |
| 73030 | <1% | 773 | $11K | |
| 80076 | <1% | 3,975 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,142 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,073 | $9K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $8K |
| 83690 | <1% | 4,958 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,512 | $8K |
| 80329 | <1% | 1,002 | $8K | |
| 87081 | <1% | 2,301 | $7K | |
| 84703 | <1% | 5,886 | $7K | |
| 85610 | <1% | 5,961 | $7K | |
| 90715 | <1% | 562 | $7K | |
| 81003 | <1% | 11,485 | $7K | |
| 73110 | <1% | 382 | $6K | |
| G2251 | Brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion | <1% | 96 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,395 | $6K |
| J3490 | Unclassified drugs | <1% | 4,589 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,524 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 476 | $6K |
| 83880 | <1% | 471 | $5K | |
| 90785 | <1% | 129 | $5K | |
| 86900 | <1% | 593 | $5K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 103 | $5K |
| 85730 | <1% | 3,812 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 83 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,857 | $5K |
| 71250 | <1% | 162 | $5K | |
| 84702 | <1% | 1,078 | $5K | |
| 87040 | <1% | 706 | $4K | |
| 93017 | <1% | 12 | $4K | |
| 97010 | <1% | 2,166 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 156 | $4K |
| 81025 | <1% | 3,437 | $4K | |
| 83605 | <1% | 784 | $4K | |
| 74022 | <1% | 244 | $4K | |
| 85379 | <1% | 1,915 | $3K | |
| 83735 | <1% | 1,967 | $3K | |
| 81001 | <1% | 6,022 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 202 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,932 | $3K |
| 80306 | <1% | 160 | $3K | |
| 87147 | <1% | 2,364 | $3K | |
| 82962 | <1% | 1,791 | $3K | |
| 82150 | <1% | 1,588 | $2K | |
| 72131 | <1% | 129 | $2K | |
| OP250 | <1% | 1,071 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 82 | $2K |
| 97161 | <1% | 49 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,181 | $2K |
| OP229 | <1% | 31 | $2K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 32 | $2K |
| 70486 | <1% | 58 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 664 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,876 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 685 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,209 | $1K |
| 72100 | <1% | 70 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $1K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 957 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,688 | $1K |
| 72110 | <1% | 55 | $1K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 19 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 75 | $1K |
| 87186 | <1% | 228 | $856.60 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,017 | $848.22 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,175 | $831.80 |
| 73502 | <1% | 43 | $827.25 | |
| 86850 | <1% | 71 | $725.20 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $694.43 |
| 76536 | <1% | 12 | $690.61 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,463 | $671.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,355 | $651.36 |
| 12001 | <1% | 12 | $641.72 | |
| 82550 | <1% | 303 | $552.37 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,259 | $510.19 |
| 85652 | <1% | 672 | $399.60 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 911 | $374.38 |
| 87077 | <1% | 144 | $367.58 | |
| 86140 | <1% | 204 | $276.86 | |
| 80061 | Lipid panel | <1% | 32 | $252.61 |
| 87807 | <1% | 73 | $246.64 | |
| 73080 | <1% | 15 | $239.09 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 149 | $238.62 |
| 85027 | <1% | 132 | $225.93 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 816 | $223.42 |
| 85055 | <1% | 15 | $216.08 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 848 | $209.20 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 76 | $203.77 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 242 | $141.64 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 66 | $123.24 |
| 85008 | <1% | 409 | $82.26 | |
| 87071 | <1% | 25 | $79.73 | |
| 86308 | <1% | 54 | $58.50 | |
| OP637 | <1% | 435 | $36.59 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 19 | $32.94 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 105 | $32.63 |
| 80178 | <1% | 12 | $31.95 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 78 | $26.92 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $19.76 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 15 | $3.00 |
| A9270 | Non-covered item or service | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialO'CONNELL, JAMES (DIRECTOR REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Inspira Medical Centers, INC. | Vineland, NJ | $227.07M |
| Inspira Medical Centers, INC. | Mullica Hill, NJ | $56.65M |
| Inspira Medical Centers, INC. | Elmer, NJ | $30.55M |
| Inspira Health Network Medical Group, P.C. | Glassboro, NJ | $5.22M |
| Inspira Medical Centers, INC. | Bridgeton, NJ | $73K |
| Inspira Medical Centers, INC. | Woodbury, NJ | $33K |
| Inspira Medical Centers, INC. | Woodbury, NJ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.